An open-label extension study of lurasidone in patients with schizophrenia previously randomized to lurasidone or risperidone

被引：0
|
作者：
Mattingly, G. [1 ]
Tocco, M. [2 ]
Cucchiaro, J. [3 ]
Xu, J. [3 ]
Pikalov, A. [3 ]
Loebel, A. [3 ]
机构：
[1] St Charles Psychiat Associates, St Charles, MO USA
[2] Sunov Pharmaceut Inc, Marlborough, MA USA
[3] Sunov Pharmaceut Inc, Ft Lee, VA USA
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2014年 / 24卷
关键词：
D O I：
10.1016/S0924-977X(14)70895-8
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P.3.d.062
引用
收藏
页码：S559 / S559
页数：1
相关论文
共 50 条
  • [41] Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
    Tocco, M.
    Pikalov, A.
    Deng, L.
    Goldman, R.
    EUROPEAN PSYCHIATRY, 2021, 64 : S165 - S166
  • [42] EFFECT OF LURASIDONE ON NEUROCOGNITIVE PERFORMANCE IN ADOLESCENTS WITH SCHIZOPHRENIA: RESULTS FROM A PLACEBO-CONTROLLED SHORT-TERM STUDY AND AN OPEN-LABEL EXTENSION STUDY
    Harvey, Philip D.
    Goldman, Robert
    Tocco, Michael
    Deng, Ling
    Cucchiaro, Josephine
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2017, 56 (10): : S175 - S176
  • [43] Lurasidone dosing in a 6-month open label long term extension study
    Liang, S.
    Pikalov, A.
    Zhao, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2020, 40 : S324 - S324
  • [44] LURASIDONE FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER WITH MIXED FEATURES: RESULTS OF A 12-WEEK OPEN-LABEL EXTENSION STUDY
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    Hopwood, M.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2019, 53 : 145 - 146
  • [45] EFFECT OF LURASIDONE ON COGNITIVE FUNCTION IN PEDIATRIC BIPOLAR DEPRESSION: RESULTS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
    Burdick, Katherine
    Tocco, Michael
    Pikalov, Andrei A.
    Deng, Ling
    Goldman, Robert S.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S248 - S248
  • [46] A PROSPECTIVE, 1-YEAR, OPEN-LABEL, FLEXIBLE DOSE STUDY OF LURASIDONE IN THE TREATMENT OF SCHIZOPHRENIA: SAFETY, TOLERABILITY, AND EFFECTIVENESS
    Hiroki, Ogo
    Masakuni, M.
    Masaaki, O.
    Cucchiaro, J.
    Siu, C.
    Loebel, A.
    SCHIZOPHRENIA BULLETIN, 2011, 37 : 305 - 306
  • [47] Lurasidone for the treatment of major depressive disorder with mixed features: results of a 12-week open-label extension study
    Stahl, S. M.
    Pikalov, A.
    Tocco, M.
    Mao, Y.
    Loebel, A.
    EUROPEAN PSYCHIATRY, 2019, 56 : S94 - S94
  • [48] EFFICACY OF LURASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DEPRESSION: RESULTS FROM A 2-YEAR OPEN-LABEL EXTENSION STUDY
    Delbello, Melissa P.
    Goldman, Robert S.
    Tocco, Michael
    Pikalov, Andrei A.
    Loebel, Antony
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2019, 58 (10): : S231 - S231
  • [49] EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE VS. PREVIOUSLY TREATED ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A TWO YEAR, OPEN-LABEL STUDY
    Correll, C. U.
    Tocco, M.
    Pikalov, A.
    Goldman, R.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2021, 55 (1_SUPPL): : 102 - 102
  • [50] EFFICACY OF LURASIDONE IN ANTIPSYCHOTIC-NAIVE VERSUS PREVIOUSLY TREATED ADOLESCENTS WITH SCHIZOPHRENIA: POST-HOC ANALYSIS OF A 2-YEAR, OPEN-LABEL STUDY
    Correll, C. U.
    Tocco, M.
    Goldman, R.
    Pikalov, A.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2022, 56 (1_SUPPL): : 206 - 206
12345